There were several dividend aristocrats that recently announced no increase in their payments to shareholders.
Pfizer (PFE), which is one of the leading pharmaceutical companies in the world, announced no increase in its annual dividends for the first time in 41 years. In the past decade, the company was used to increasing its dividend payments to shareholders every December. It comes as no surprise to me that PFE is not raising its dividends. The company needs to increase its drug pipeline either through research or acquisitions as most of its drugs will be facing serious generic competition after they go off patent in 2011. Furthermore, the rising payout and stagnating earnings show danger to the dividend growth investor. In order to maintain its dividend aristocrat status, Pfizer has to increase its dividends by November 2009.
Another stock that announced no increase in its dividends was State Street (STT), which received 5 billion from the Treasury several months ago. The company broke a 27 year streak of two dividend increases per year. In order to maintain its dividend aristocrat status, State Street has to increase its dividends by the end of 2010. As a holder of STT, I am planning to be a seller at $51, which is my breakeven price as I fear that TARP might limit dividend payments for financial companies which received funds from the Treasury.
Progressive (PGR), which is a dividend aristocrat as well, announced that it won’t be paying a dividend in 2008, which terminates its status of a consistent dividend performer.
As a dividend growth investor an unchanged dividend is not necessarily bearish news. Most companies don’t raise their dividends every year, but still could achieve a decent dividend growth rate. If I could exit the position at least at breakeven however, I would most probably invest in companies which could support an increasing dividend payments even during cyclical downturns.
Relevant Articles:
- Why do I like Dividend Aristocrats?
- State Street Corporation (STT) Dividend Stock Analysis.
Popular Posts
-
Good Morning, Subscribers to the Dividend Growth Investor newsletter received ten ideas for research on Sunday. The newsletter included in...
-
I am frequently asked by readers about resources I use. While I have discussed before the resources I use to monitor my holdings, and I hav...
-
I review the list of dividend increases weekly, as part of my portfolio monitoring process. I usually narrow the list down to companies with...
-
As part of my monitoring process , I review the list of dividend increases every week. I usually focus my attention on the companies that h...
-
Earlier this month, I received questions from a few readers about CVS and Walgreen’s. The share prices behind both companies are taking a be...
-
I have spent the last month discussing CVS Health (CVS) and Walgreen’s (WBA) with a lot of readers on my site . I have spent even more time ...
-
Walgreens Boots Alliance, Inc. (WBA) operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pha...
-
Planning your retirement is one of the most challenging exercises in the world. There are plenty of ways, methods and advisors, who try to i...
-
As dividend investors, we focus on identifying and selecting the companies to include in our divided portfolios. The ultimate goal is achiev...
-
The March 2019 edition of the Dividend Growth Investor newsletter comes out this Sunday, March 24. This will be the ninth edition of the di...
